Objective:

To assess risk stratification and preventive strategies in cardiomyopathies, aiming to mitigate arrhythmic sudden cardiac death and heart failure progression.

Key Findings:

• Patients with ≥3 modifiable cardiovascular risk factors had the highest hsTnT/I levels and increased all-cause mortality.
• Lower BMI in non-ischemic dilated cardiomyopathy patients was associated with worse cardiovascular outcomes.
• Complete right bundle branch block was rare in young individuals, with specific ECG findings warranting further evaluation.
• Predictive factors for arrhythmic events included pathological Q waves, prolonged QRS duration, and increased LV volume.
• No significant link was found between vigorous exercise and the development of LV systolic dysfunction or arrhythmias.
• 32.7% of individuals with cardiometabolic conditions exhibited myocardial fibrosis, with the highest prevalence in hypertensive patients.
• SGLT2 inhibitors were associated with lower risks of all-cause death and heart failure hospitalization in hypertrophic cardiomyopathy patients.

Interpretation:

The studies underscore the importance of modifiable risk factors, body weight, and specific ECG findings in predicting outcomes in cardiomyopathies, while also highlighting the potential benefits of SGLT2 inhibitors in improving patient outcomes.

Limitations:

• The studies were conducted in specific populations, which may limit generalizability.
• Follow-up durations varied, potentially affecting outcome assessments.
• Some studies relied on observational data, which may introduce bias and limit causal inferences.

Conclusion:

Risk stratification and preventive strategies are crucial in managing cardiomyopathies, with lifestyle modifications and pharmacotherapy, particularly SGLT2 inhibitors, showing promise in improving patient outcomes.